Table 2.
Basal levels of haemodynamic variables during each of the three experimental periods in Protocol 2 (n=5 per group)
|
Group 1 |
Group 2 |
|||||
|---|---|---|---|---|---|---|
| Control period | Vehicle 1 treatment | Vehicle 2 treatment | Control period | L-NNA treatment | L-NNA+Ibuprofen | |
| MAP (mmHg) | 66±3 | 73±2 | 71±2 | 65±4 | 96±3*** | 88±7 |
| HR (beats min−1) | 286±2 | 263±7* | 246±8 | 261±15 | 210±14* | 226±21 |
| RBF (ml min−1) | 26±3 | 24±2 | 23±2 | 25±1 | 19±2 | 22±3 |
| MBF (units) | 41±11 | 30±6 | 33±7 | 39±12 | 16±4 | 29±10 |
Abbreviations: ANOVA, analysis of variance; HR, heart rate; MAP, mean arterial pressure; MBF, medullary blood flow measured by laser Doppler flowmetry; RBF, renal blood flow.
Results are presented as mean±s.e.
*
P⩽0.05,
***
P⩽0.005 versus the previous period.
These P-values were derived from specific contrasts made from partitioned ANOVA, and were conservatively adjusted to account for multiple comparisons using the Bonferroni method (Ludbrook, 1998).